December 2023: Brad Finstad Voted Against H.R. 5378, The Bipartisan “Lower Costs, More Transparency Act,” Which Increased Funding For Health Programs To Increase Price Transparency For Hospitals, Health Insurance Companies, And Pharmacies

December 2023: Finstad Voted Against H.R. 5378, The Bipartisan “Lower Costs, More Transparency Act”

December 2023: Finstad Voted Against H.R. 5378, The Bipartisan Lower Costs, More Transparency Act. In December 2023, Congressman Brad Finstad voted against: “Rodgers, R-Wash., motion to suspend the rules and pass the bill, as amended, that would extend, for just over two years, funding for several public health programs, including community health centers, and it includes a wide range of provisions intended to help reduce consumer health care and drug costs by increasing pricing transparency and requiring certain other actions. Among other provisions, it would require health insurance companies and pharmacy benefit managers to regularly provide detailed information on prescription drug costs and the drug rebates they receive to provide pricing transparency, and it codifies and expands two sets of Trump administration pricing transparency rules — one dealing with hospital pricing transparency, which it extends to other medical facilities while incorporating new enforcement mechanisms, and the other focused on pricing transparency for employer-based group health plans and insurers. The bill would also prohibit certain pharmacy benefit manager pricing practices with respect to Medicaid, and it includes provisions intended to reduce health care costs for individuals, employer-sponsored health plans, and the federal government. To implement the bill's provisions, the measure would provide a total of $65 million for the Health and Human Services and Treasury departments, and $35 million for the Labor Department.” The motion was agreed to by a vote of 320-71. [H.R. 5378, Vote #708, 12/11/23; CQ, 12/11/23]

  • December 2023: Healthcare Dive Headline: “House Passes Bill Targeting Price Transparency, Site-Neutral Payments, PBMs.” [Healthcare Dive, 12/12/23]

H.R. 5738 Banned Pharmaceutical Benefit Managers From “Spread Pricing,” Where PBMs Charge More Than They Pay For Drugs In Medicaid

Healthcare Dive: “The Legislation Also Includes Price Transparency Reforms For PBMs […] PBMs Would Be Banned From Spread Pricing, When The PBMs Charge More Than They Pay For Drugs In Medicaid.” “The legislation also includes price transparency reforms for PBMs — the drug middlemen that sit between health insurers, drug manufacturers and pharmacies. PBMs negotiate drug rebates with manufacturers in exchange for placing them on payer clients’ formularies. PBMs would be banned from spread pricing, when the PBMs charge more than they pay for drugs in Medicaid. They would also be required to disclose rebates, fees or other types of compensation to brokers. The drug middlemen have been the target of federal scrutiny recently for their role in rising drug prices. Several Congressional committees and the Federal Trade Commission have launched investigations into PBMs.” [Healthcare Dive, 12/12/23]

  • U.S. House Energy and Commerce Committee: The Lower Costs, More Transparency Act “Would Ban Spread Pricing In Medicaid And Ensure The Accuracy Of The National Average Drug Acquisition Cost (NADAC) Survey In Medicaid […] The Policy Would Require Pharmacies To Complete The Survey And Report Actual Acquisition Costs For Drugs.” “Introduced as H.R. 1613 by Reps. Carter (R-GA-1), Gonzalez (D-TX-34), Stefanik (R-NY21), Ross (D-NC-2), Allen (R-GA-12), and Auchincloss (D-MA-4), this section would ban spread pricing in Medicaid and ensure the accuracy of the National Average Drug Acquisition Cost (NADAC) survey in Medicaid. Specifically, this section would prohibit PBMs that contract with Medicaid Managed Care Organizations (MCOs) from spread pricing. In lieu of spread pricing, the language would clarify that states should reimburse PBMs contracting with MCOs for an administrative fee for managing the pharmacy benefit for Medicaid beneficiaries. Additionally, this section supports NADAC pricing in Medicaid. Many states use the NADAC price survey to determine actual acquisition costs, with accuracy of the survey contingent on pharmacies filling out the data requested by the survey. The policy would require pharmacies to complete the survey and report actual acquisition costs for drugs.” [U.S. House Energy and Commerce Committee, accessed 7/9/26]

U.S. Centers for Medicare & Medicaid: “If Spread Pricing Is Not Appropriately Monitored And Accounted For, A PBM Can Profit From Charging Health Plans An Excess Amount Above The Amount Paid To The Pharmacy Dispensing A Drug, Which Increases Medicaid Costs For Taxpayers.” “Spread pricing occurs when health plans contract with pharmacy benefit managers (PBMs) to manage their prescription drug benefits, and PBMs keep a portion of the amount paid to them by the health plans for prescription drugs instead of passing the full payments on to pharmacies. Thus, there is a spread between the amount that the health plan pays the PBM and the amount that the PBM reimburses the pharmacy for a beneficiary’s prescription. If spread pricing is not appropriately monitored and accounted for, a PBM can profit from charging health plans an excess amount above the amount paid to the pharmacy dispensing a drug, which increases Medicaid costs for taxpayers.” [U.S. Centers for Medicare & Medicaid, Press Release, 5/15/19]

H.R. 5738 Would Grant The Community Health Center Fund $4.4 Billion Per Year Through 2025, Including More Than $9 Million In Federal Investment For 3 Federal Community Health Centers Serving More Than 86,000 Patients In MN-01

H.R. 2738 Would Grant The Community Health Center Fund $4.4 Billion Per Year Through 2025

U.S. House Energy and Commerce: The Lower Costs, More Transparency Act “Would Extend The Community Health Center Fund Through Calendar Year 2025 At $4.4 Billion Per Year And National Health Service Corps Through Calendar Year 2025 At $350 Million Per Year.” “Sec. 301. Extension for Community Health Centers, the National Health Service Corps, and Teaching Health Centers that Operate GME Programs. Introduced as H.R. 2559 by Reps. Joyce (R-PA-13), Blunt Rochester (D-DE-At-Large), Stefanik (R-NY-21), and Fletcher (D-TX-7), this section would extend the Community Health Center Fund through calendar year 2025 at $4.4 billion per year and National Health Service Corps through calendar year 2025 at $350 million per year. This section would also extend the Teaching Health Center Graduate Medical Education Program for FY24-30, beginning at $175 million in FY24 and increasing to $300 million for each of FY28, 29, and 30. This section also allows HRSA to utilize carryover funds for the THCGME program for FY24 and FY25.” [U.S. House Energy and Commerce, accessed 7/9/26]

  • National Association Of Community Health Centers: “The Federal Community Health Center Fund (CHCF) […] Supports Qualified Community Healthcare Facilities That Provide Care In Medically Underserved Areas Or To Medically Underserved Populations.” “The federal Community Health Center Fund (CHCF), operated by the Health Resources and Services Administration (HRSA), supports qualified community healthcare facilities that provide care in medically underserved areas or to medically underserved populations. Community Health Centers receive funding from a variety of sources, including Medicare, Medicaid, private insurance, self-pay, state and local grants, federal CHCF grants, and other grants. CHCF funding is the largest dedicated source of funding and the second-largest funding source overall, after Medicaid.” [National Association of Community Health Centers, Press Release, March 2023]

November 2024: Minnesota’s 1st Congressional District Received More Than $9 Million In Federal Investment For Its Three Federal Community Health Centers, Which Served More Than 86,000 Patients

November 2024: Minnesota’s 1st Congressional District Received More Than $9 Million In Federal Investment For Its Three Federal Community Health Centers, Which Served More Than 86,000 Patients. [National Association of Community Health Centers, Minnesota’s 1st Congressional District, November 2024]

Image: see original report, p. 70

[National Association of Community Health Centers, Minnesota’s 1st Congressional District, November 2024]

November 2024: Minnesota’s 1st Congressional District Received $9,782,285 In Federal Investment For Its Three Federal Community Health Centers. [National Association of Community Health Centers, Minnesota’s 1st Congressional District, November 2024]

Federal Community Health Center In Minnesota’s 1st Congressional District

Federal Community Health Center

City

Zip Code

Community Health Service Inc

Rochester

55904

Open Door Health Center

Mankato

56001

Rural Health Care, Inc

Worthington

56187

Total Federal Investment:

$9,782,285

[National Association of Community Health Centers, Minnesota’s 1st Congressional District, November 2024]

H.R. 5738 Would Increase Hospital Price Transparency, Requiring Clear Price Disclosures

Healthcare Dive: “The House Of Representatives Voted On Monday Night To Pass A Bipartisan Healthcare Policy Bill To Make Hospital Prices More Transparent And Ban Some Practices By Pharmacy Benefit Managers.” “The House of Representatives voted on Monday night to pass a bipartisan healthcare policy bill to make hospital prices more transparent and ban some practices by pharmacy benefit managers. The bill, called the Lower Costs, More Transparency Act, would also equalize payments for drugs in Medicare regardless if they’re administered in an hospital outpatient departments or doctor’s offices. It would also delay payment cuts for hospitals that treat high volumes of uninsured patients. The cuts, which were expected to come due next year, are now delayed until 2026.” [Healthcare Dive, 12/12/23]

  • Healthcare Dive: “The Bill Would Also Require Hospitals, Insurers And Imaging Providers To Disclose Prices For Services In Consumer-Friendly Formats.” “The House of Representatives voted on Monday night to pass a bipartisan healthcare policy bill to make hospital prices more transparent and ban some practices by pharmacy benefit managers. The bill, called the Lower Costs, More Transparency Act, would also equalize payments for drugs in Medicare regardless if they’re administered in an hospital outpatient departments or

doctor’s offices. […] The bill would also require hospitals, insurers and imaging providers to disclose prices for services in consumer-friendly formats.” [Healthcare Dive, 12/12/23]

Republican Chair Of The House Energy And Commerce Committee Rep. Cathy Rodgers: “This Bipartisan Legislation Delivers On Our Commitment To Lowering Health Care Costs And Providing Increased Transparency For Patients Something 95 Percent Of Americans Support.” “The bill now heads to the Senate. Lawmakers praised the bill, which passed on a 320-71 vote. ‘This bipartisan legislation delivers on our commitment to lowering health care costs and providing increased transparency for patients — something 95 percent of Americans support,’ said Rep. Cathy Rodgers, R-Wash., chair of the House Energy and Commerce Committee, in a statement.” [Healthcare Dive, 12/12/23]

Source report (PDF)